These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 27270607)
1. Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model. Hoang NT; Kadonosono T; Kuchimaru T; Kizaka-Kondoh S Cancer Sci; 2016 Aug; 107(8):1151-8. PubMed ID: 27270607 [TBL] [Abstract][Full Text] [Related]
2. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia. McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Réjiba S; Bigand C; Parmentier C; Hajri A Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409 [TBL] [Abstract][Full Text] [Related]
4. Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice. Matsumoto S; Kishimoto S; Saito K; Takakusagi Y; Munasinghe JP; Devasahayam N; Hart CP; Gillies RJ; Mitchell JB; Krishna MC Cancer Res; 2018 Jul; 78(14):3783-3792. PubMed ID: 29792309 [TBL] [Abstract][Full Text] [Related]
5. Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Onishi H; Morifuji Y; Kai M; Suyama K; Iwasaki H; Katano M Cancer Sci; 2012 Jul; 103(7):1272-9. PubMed ID: 22486854 [TBL] [Abstract][Full Text] [Related]
6. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642 [TBL] [Abstract][Full Text] [Related]
7. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Kotopoulis S; Delalande A; Popa M; Mamaeva V; Dimcevski G; Gilja OH; Postema M; Gjertsen BT; McCormack E Mol Imaging Biol; 2014 Feb; 16(1):53-62. PubMed ID: 23877869 [TBL] [Abstract][Full Text] [Related]
8. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Inoue M; Mukai M; Hamanaka Y; Tatsuta M; Hiraoka M; Kizaka-Kondoh S Int J Oncol; 2004 Sep; 25(3):713-20. PubMed ID: 15289874 [TBL] [Abstract][Full Text] [Related]
9. Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer. Kramer RM; Russell J; Humm JL Cancer Biother Radiopharm; 2015 Sep; 30(7):299-304. PubMed ID: 26203552 [TBL] [Abstract][Full Text] [Related]
10. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Kizaka-Kondoh S; Itasaka S; Zeng L; Tanaka S; Zhao T; Takahashi Y; Shibuya K; Hirota K; Semenza GL; Hiraoka M Clin Cancer Res; 2009 May; 15(10):3433-41. PubMed ID: 19417024 [TBL] [Abstract][Full Text] [Related]
11. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081 [TBL] [Abstract][Full Text] [Related]
12. miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer. Liu F; Liu B; Qian J; Wu G; Li J; Ma Z Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):520-529. PubMed ID: 28459992 [TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Wang ZH; Chen H; Guo HC; Tong HF; Liu JX; Wei WT; Tan W; Ni ZL; Liu HB; Lin SZ Int J Oncol; 2011 Nov; 39(5):1123-31. PubMed ID: 21743963 [TBL] [Abstract][Full Text] [Related]
14. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924 [TBL] [Abstract][Full Text] [Related]
15. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922 [TBL] [Abstract][Full Text] [Related]
16. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling. Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403 [TBL] [Abstract][Full Text] [Related]
17. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma. Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177 [TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549 [TBL] [Abstract][Full Text] [Related]
19. [A Case of Primary Cancer of the Pancreas and Colon Treated with the Combination of Gemcitabine and TS-1]. Koyama M; Kinoshita A; Tanaka K; Koike K; Nishino H Gan To Kagaku Ryoho; 2016 Mar; 43(3):369-71. PubMed ID: 27067858 [TBL] [Abstract][Full Text] [Related]
20. Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways. Wang F; Tian X; Zhang Z; Ma Y; Xie X; Liang J; Yang C; Yang Y Int J Cancer; 2018 May; 142(9):1938-1951. PubMed ID: 29238973 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]